Zacks • 2 months ago
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
TheStreet.com • 3 months ago
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
Forbes • 3 months ago
Breast cancer patients sometimes end up dying when their tumors spread all the way to the brain. Some very good drugs already exist for patients with breast cancer, especially ones with tumors that overexpress the HER2 marker, but that success has raised a new question: Can drugmakers take another step,
Capital Cube • 3 months ago
Categories: Yahoo Finance Get free summary analysis Puma Biotechnology, Inc. reports financial results for the quarter ended September 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -65.78 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. PBYI-US‘s earnings ... Read more (Read more...)
Motley Fool • 3 months ago
Is shareholder dilution always a bad thing? What does it mean for you as an individual investor? What does it mean for activist investors?
24/7 Wall St. • 3 months ago
Now that the U.S. presidential election is over and markets have recovered to their highs, there are still some stocks holding back the markets from breaking even higher.
Insider Monkey • 3 months ago
Puma Biotechnology Inc (NYSE:PBYI) just announced its abstract for an upcoming 2016 San Antonio Breast Cancer Symposium (SABCS), which will take place on December 6 – 10, 2016, in San Antonio, Texas. The company took a dive on the announcement, and while today’s market has seen a bit of early morning strength, it’s far from […]
PBYI : Summary for Puma Biotechnology Inc - Yahoo Finance
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||36.45 x 100|
|Ask||36.70 x 100|
|Day's Range||33.65 - 36.20|
|52 Week Range||19.74 - 73.27|
|PE Ratio (TTM)||-4.44|
|Earnings Date||Feb 27, 2017 - Mar 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||86.33|